Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium In Effervescent Tablets: Formulation Strategies, Disintegration Mechanisms, And Performance Optimization

NOV 17, 202659 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose Sodium (CCS), a cross-linked polymer of carboxymethylcellulose sodium, serves as a critical superdisintegrant in effervescent tablet formulations, enabling rapid disintegration and enhanced drug release kinetics. While traditionally employed at 0.5–5% w/w in conventional tablets 11, effervescent systems demand specialized formulation approaches to balance the competing requirements of structural integrity during storage and rapid dissolution upon contact with aqueous media. This article examines the molecular mechanisms underlying CCS functionality in effervescent matrices, quantitative performance benchmarks from patent literature, and advanced formulation strategies for optimizing bioavailability in acid-sensitive and taste-masked delivery systems.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Structural Characteristics Of Croscarmellose Sodium In Effervescent Systems

Croscarmellose Sodium is synthesized through cross-linking reactions of carboxymethylcellulose sodium chains, yielding a three-dimensional hydrophilic polymer network with exceptional water uptake capacity 11. The cross-linked architecture imparts mechanical resilience while maintaining rapid swelling kinetics—a dual functionality essential for effervescent tablets that must withstand compaction forces yet disintegrate within seconds in aqueous environments. In effervescent formulations, CCS concentrations typically range from 2–6% w/w 1, significantly higher than conventional tablet applications, to counteract the hygroscopic nature of effervescent excipients (e.g., sodium bicarbonate, citric acid) and ensure consistent disintegration performance under variable humidity conditions.

The polymer's carboxylate functional groups (–COO⁻Na⁺) exhibit pH-dependent ionization, with maximum swelling occurring at pH 5–8 where electrostatic repulsion between anionic chains drives rapid water imbibition 3. This property proves advantageous in effervescent systems where CO₂ generation transiently lowers local pH; the subsequent pH rebound accelerates CCS swelling and tablet matrix disruption. Patent data demonstrate that CCS-containing effervescent tablets achieve >80% drug release within 10 minutes in 0.02N HCl at 37°C when CCS content exceeds 3% w/w 6, compared to 45–60% release for formulations using alternative disintegrants like sodium starch glycolate 2.

Key structural parameters influencing CCS performance in effervescent tablets include:

  • Degree of cross-linking: Higher cross-link density (typically 0.5–2 mol% divinyl sulfone) reduces solubility while maintaining swelling capacity, preventing premature dissolution during tablet storage 11.
  • Particle size distribution: CCS grades with D₅₀ = 30–50 μm exhibit optimal balance between compressibility and disintegration speed, as finer particles enhance surface area for water penetration but may compromise powder flow during tableting 1.
  • Moisture content: Pharmaceutical-grade CCS contains ≤10% residual moisture (USP specification); effervescent formulations require CCS with <5% moisture to minimize premature acid-base reactions during storage 3.

Comparative studies reveal that CCS outperforms crospovidone and sodium starch glycolate in effervescent matrices due to superior resistance to ionic strength effects—effervescent reactions generate high local concentrations of sodium ions (>0.5 M), which suppress swelling of non-cross-linked disintegrants but minimally affect CCS performance 2.

Disintegration Mechanisms And Kinetics In Effervescent Tablet Formulations

The disintegration mechanism of CCS in effervescent tablets involves synergistic interactions between polymer swelling and gas generation. Upon water contact, CCS particles rapidly imbibe water (swelling ratio 5–10× dry volume within 30 seconds 3), creating internal hydrostatic pressure that fractures the tablet matrix. Simultaneously, effervescent excipients undergo acid-base neutralization (e.g., NaHCO₃ + citric acid → sodium citrate + CO₂ + H₂O), generating CO₂ bubbles that propagate through CCS-induced microcracks and accelerate matrix disintegration.

Quantitative disintegration studies demonstrate concentration-dependent kinetics:

  • 1–2% CCS: Disintegration time (DT) = 180–300 seconds; incomplete matrix disruption with residual agglomerates 1.
  • 3–4% CCS: DT = 45–90 seconds; uniform dispersion with <10% residual particles >500 μm 6.
  • 5–6% CCS: DT = 20–40 seconds; risk of premature disintegration during handling if tablet hardness <50 N 3.

The optimal CCS concentration for effervescent tablets typically falls within 3–4% w/w, balancing rapid disintegration with adequate mechanical strength (hardness 60–100 N, friability <0.8%) 1. Patent formulations employing CCS at 3.5% w/w in combination with 400 mg sodium bicarbonate achieve 75% drug dissolution within 5 minutes and >90% within 10 minutes in simulated gastric fluid (pH 1.2, 37°C, 100 rpm paddle method) 10.

Advanced mechanistic insights from fluidized-bed coating studies reveal that CCS applied as an aqueous slurry (5–10% w/v) during granulation forms a continuous film around active pharmaceutical ingredient (API) particles, providing dual functionality as both a disintegrant and a taste-masking barrier 3. This approach proves particularly effective for bitter APIs (e.g., acetaminophen, ibuprofen), where CCS coatings at 8–12% w/w relative to API mass achieve >85% taste-masking efficacy in sensory panels while maintaining tablet disintegration times <60 seconds 4. The coating process requires precise control of inlet air temperature (50–60°C), spray rate (5–10 g/min), and atomization pressure (1.5–2.0 bar) to prevent CCS film cracking and ensure uniform coverage 3.

Formulation Strategies For Croscarmellose Sodium In Effervescent Tablets

Intragranular Versus Extragranular Addition Approaches

The distribution of CCS between intragranular (within granules) and extragranular (added post-granulation) phases critically influences disintegration performance. Patent formulations demonstrate that splitting CCS allocation—typically 60–70% intragranular and 30–40% extragranular—optimizes both granule integrity during drying and final tablet disintegration 1. Intragranular CCS (2–3% w/w) incorporated as an aqueous slurry during wet granulation coats API particles and promotes granule porosity, while extragranular CCS (1–2% w/w) blended with lubricants (e.g., magnesium stearate 0.5–1%) ensures rapid water penetration into the compressed tablet core 2.

Comparative dissolution profiles illustrate this effect:

  • 100% intragranular CCS (4% total): T₅₀ (time for 50% dissolution) = 8.5 minutes; granule swelling impedes water ingress to tablet core 1.
  • 100% extragranular CCS (4% total): T₅₀ = 6.2 minutes; inadequate granule disintegration leads to API agglomeration 1.
  • 60/40 intra/extragranular split (4% total): T₅₀ = 3.8 minutes; synergistic disintegration from both granule and tablet matrix levels 2.

For effervescent tablets containing water-soluble APIs (e.g., ascorbic acid, paracetamol), intragranular CCS content may be reduced to 1–2% w/w as API dissolution contributes to matrix disruption 1. Conversely, poorly soluble APIs (e.g., ibuprofen, naproxen) require higher intragranular CCS (3–4% w/w) to ensure adequate particle deaggregation and surface area exposure for dissolution 3.

Co-Processing With Microcrystalline Cellulose And Alginate Complexes

Patent literature reveals that co-processed excipients combining microcrystalline cellulose (MCC), CCS, and calcium-sodium alginate complexes deliver superior performance in effervescent suspension tablets 1. A representative formulation comprises:

  • 10–50% MCC (grade PH-101, D₅₀ = 50 μm): Provides compressibility and acts as a suspending agent post-disintegration 1.
  • 3–6% CCS: Primary disintegrant ensuring <60-second disintegration time 1.
  • 10–50% co-processed MCC-alginate (75–95% MCC, 5–25% Ca-Na alginate): Enhances tablet hardness (70–120 N) while maintaining rapid disintegration through alginate's pH-sensitive swelling 1.

The alginate component undergoes ion exchange in aqueous media (Ca²⁺ → Na⁺), generating additional osmotic pressure that synergizes with CCS swelling. Tablets formulated with this ternary system achieve disintegration times of 35–50 seconds and form stable suspensions with <5% sedimentation after 5 minutes, suitable for pediatric and geriatric populations requiring liquid dosage forms 1. Compression forces of 8–12 kN yield tablets with hardness 80–100 N and friability <0.5%, meeting USP specifications for effervescent tablets 2.

Moisture Control And Stability Optimization Strategies

Effervescent tablets face inherent stability challenges due to the hygroscopicity of acid-base excipients and the moisture sensitivity of CCS. Accelerated stability studies (40°C/75% RH, 6 months) demonstrate that CCS-containing effervescent formulations exhibit:

  • Hardness increase: +15–25% due to moisture-induced CCS cross-linking and effervescent excipient caking 5.
  • Disintegration time prolongation: +30–50% as absorbed moisture plasticizes CCS and reduces swelling capacity 5.
  • CO₂ loss: 5–10% due to premature acid-base reaction, reducing effervescence intensity 10.

Mitigation strategies include:

  1. Low-moisture CCS grades: Specification of CCS with ≤3% moisture content reduces water activity in the tablet matrix 3.
  2. Hydrophobic lubricants: Sodium stearyl fumarate (0.5–1% w/w) provides superior moisture barrier properties compared to magnesium stearate, reducing water vapor transmission rate by 40–60% 10.
  3. Barrier packaging: Aluminum-aluminum blister packs with desiccant sachets (silica gel, 1–2 g per 10 tablets) maintain tablet moisture content <2% over 24-month shelf life 5.
  4. Alkaline buffering agents: Addition of 0.5–1% magnesium oxide elevates tablet microenvironment pH to 8–9, suppressing CCS hydrolysis and preserving disintegration performance 5.

Formulations incorporating these strategies demonstrate <10% change in disintegration time and <5% drug content variation after 24 months storage at 25°C/60% RH 5.

Applications Of Croscarmellose Sodium In Specialized Effervescent Tablet Systems

Taste-Masked Effervescent Formulations For Pediatric Use

CCS enables development of taste-masked effervescent tablets through fluidized-bed coating of bitter APIs with CCS-binder-plasticizer films 3. A representative process involves:

  1. Substrate preparation: Crystalline API (e.g., acetaminophen, D₅₀ = 100–200 μm) loaded into fluidized-bed coater 3.
  2. Coating solution: 8–12% w/v CCS, 2–4% w/v hydroxypropyl cellulose (binder), 0.5–1% w/v glycerin (plasticizer) in purified water 4.
  3. Spray coating: Inlet temperature 55–60°C, product temperature 40–45°C, spray rate 8–12 g/min, atomization pressure 1.8–2.2 bar 3.
  4. Drying: Continued fluidization at 50°C for 15–20 minutes to reduce moisture content to <3% 3.

Coated particles exhibit 10–15% weight gain and achieve 80–90% taste-masking efficacy in human sensory panels (n=15–20 subjects, paired comparison test) 4. When compressed into effervescent tablets (CCS-coated API 40%, sodium bicarbonate 30%, citric acid 15%, MCC 10%, flavoring 3%, lubricant 2%), the formulations disintegrate within 45–60 seconds and release >85% API within 10 minutes, with <15% subjects detecting bitterness 3. The CCS coating remains intact during tablet compression (8–10 kN force) but rapidly disintegrates upon water contact due to CO₂ bubble-induced mechanical disruption 4.

Sustained-Release Effervescent Tablets With Croscarmellose Sodium

Counterintuitively, CCS can be incorporated into sustained-release effervescent systems through combination with hydrophilic polymers (e.g., hypromellose, hydroxypropyl cellulose) and hydrophobic bases (e.g., ethyl cellulose, glyceryl behenate) 7. A patented formulation comprises:

  • Drug: 0.5–70% w/w 7
  • CCS: 3–20% w/w (controls initial burst release) 7
  • Sodium carbonate: 1–20% w/w (effervescent agent with slower reaction kinetics than bicarbonate) 7
  • Hypromellose (HPMC 2208, 100,000 cP): 1–20% w/w (forms viscous gel layer retarding drug diffusion) 7
  • Magnesium oxide: 1–20% w/w (alkaline buffer maintaining pH 8–10 for sustained CCS activity) 7

This system achieves biphasic release: rapid initial release (30–40% in first hour) driven by CCS disintegration and effervescence, followed by sustained release (remaining 60–70% over 6–12 hours) controlled by HPMC gel erosion 7. The formulation proves effective for drugs requiring both rapid onset (e.g., analgesics) and prolonged duration (e.g., anti-inflammatory agents), with in vivo studies demonstrating Tmax = 1.5–2 hours and therapeutic plasma levels maintained for 10–14 hours 9.

Proton Pump Inhibitor Effervescent Formulations

CCS plays a critical role in effervescent formulations of acid-labile proton pump inhibitors (PPIs) such as omeprazole and lansoprazole 10. These formulations employ high concentrations of sodium bicarbonate (≥400 mg per dose) to rapidly elevate gastric pH above 5, protecting the PPI from acid degradation during dissolution 10. CCS at 2–6% w/w ensures rapid tablet disintegration (<90 seconds) and uniform bicarbonate dispersion, achieving gastric pH >5 within 5 minutes of administration 12.

A representative omeprazole effervescent capsule formulation contains 10:

  • Immediate-release powder: 40 mg omeprazole magnesium, 400 mg sodium bicarbonate (4.8 mEq), 30 mg CCS, 10 mg sodium stearyl fumarate 10
  • Sustained-release mini-tablets (3×): Each containing 13.3 mg omeprazole base, 140 mg filler (lactose or dicalcium phosphate), 30–80 mg release-controlling polymer (HPMC or ethyl cellulose), 2 mg lubricant 10

Upon capsule opening and dispersion in water, the immediate-release powder disintegrates within 30–45 seconds, rapidly neutralizing gastric acid, while the mini-tablets provide sustained omeprazole release over 4–6 hours 12. Clinical studies demonstrate 35–40% improvement in omeprazole bioavailability compared to enteric-coated tablets, attributed to reduced acid degradation and enhanced absorption in the neutral pH environment 10.

Comparative Performance: Croscarmellose Sodium Versus Alternative Disintegrants In Effervescent Systems

Systematic comparison of superdisintegrants in effervescent tablet formulations reveals distinct performance profiles 2:

**Croscarmellose Sodium (3–4% w/

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CorporationRapidly disintegrating effervescent suspension tablets for pediatric and geriatric populations requiring liquid dosage forms, suitable for both water-soluble and water-insoluble pharmaceuticals.Ac-Di-SolAchieves tablet disintegration within 35-60 seconds when used at 3-6% w/w in effervescent suspension tablets, combined with microcrystalline cellulose and calcium-sodium alginate complex to form stable suspensions with less than 5% sedimentation after 5 minutes.
FMC CorporationTaste-masked effervescent tablets for bitter active pharmaceutical ingredients such as acetaminophen and ibuprofen, particularly for pediatric applications requiring palatability and rapid dissolution.Ac-Di-Sol Taste Masking SystemProvides dual functionality as taste-masking coating (8-12% w/v aqueous slurry) and tablet disintegrant, achieving 80-90% taste-masking efficacy for bitter APIs while maintaining tablet disintegration times under 60 seconds in effervescent formulations.
Shionogi & Co. Ltd.Extended-release effervescent systems for drugs requiring both rapid onset and prolonged therapeutic duration, such as analgesics and anti-inflammatory agents, enduring gastrointestinal peristaltic movement.Sustained Release Effervescent FormulationEnables biphasic drug release with 30-40% rapid initial release in first hour followed by sustained release over 6-12 hours when combined with hypromellose and magnesium oxide at 3-20% w/w croscarmellose sodium concentration.
Santarus Inc.Acid-labile proton pump inhibitor delivery systems requiring immediate gastric pH neutralization to prevent drug degradation, suitable for treatment of gastroesophageal reflux disease and peptic ulcers.Omeprazole Effervescent CapsuleAchieves gastric pH elevation above 5 within 5 minutes and 35-40% improvement in omeprazole bioavailability compared to enteric-coated tablets, using 2-6% w/w croscarmellose sodium with 400mg sodium bicarbonate for rapid disintegration under 90 seconds.
Reference
  • Pharmaceutical suspension tablet compositions
    PatentWO1999030689A1
    View detail
  • Pharmaceutical suspension tablet compositions
    PatentInactiveHK1033543A
    View detail
  • Croscarmellose taste masking
    PatentWO2000002536A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png